The main purpose of this protocol is to provide expanded access to the study drug
(Ponatinib/AP24534) for people with imatinib-, dasatinib-, and nilotinib-
resistant/intolerant Philadelphia Chromosome Positive (Ph+) Leukemias. The other purpose of
this protocol is to monitor the safety of the study drug in people with Ph+ Leukemias that
have not responded to prior treatment.